Davunetide Research: What 233 Studies Show (2026) | RetatrutideCompare

Davunetide — 233 studies indexed on PubMed. Stabilizes microtubules via tubulin binding, particularly in tauopathy models. Half-life: Minutes (intranasal). FDA status: Investigational.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Davunetide?

There are approximately 233 studies indexed on PubMed that mention Davunetide (NAP, AL-108), based on a search last updated 2026-06-18.

Is Davunetide FDA-approved?

FDA status: Investigational.

How does Davunetide work?

Stabilizes microtubules via tubulin binding, particularly in tauopathy models.

Stabilizes microtubules via tubulin binding, particularly in tauopathy models.

Reference facts

Also known as
NAP, AL-108, NAPVSIPQ
Category
Nootropic & Cognitive
Mechanism of action
Stabilizes microtubules via tubulin binding, particularly in tauopathy models.
Targets
Tubulin / microtubules
Indications under research or approved
Phase 2/3 in progressive supranuclear palsy (failed primary endpoint 2014); ongoing research in ADNP syndrome
Regulatory status (reference entry)
Investigational
Half-life
Minutes (intranasal)
Sequence
NAPVSIPQ
Sequence notes
Octapeptide active fragment of activity-dependent neuroprotective protein (ADNP).
Molecular weight (Da)
825
Originator / sponsor
Originally Allon Therapeutics
First reported
1999

Primary References

Explore research articles about Davunetide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.